InSilico Medicine Cayman TopCo (英矽智能; “INSILICO”) published an update on 15 July 2026 detailing the composition of its six-member board and the allocation of roles across four key committees.

The board consists of two executive directors—Aleksandrs Zavoronkovs, Ph.D., and Feng Ren, Ph.D.—one non-executive director, Chuen Yan Leung, Ph.D., and three independent non-executive directors: Denitsa Milanova, Ph.D.; Jingsong Wang, Ph.D.; and Roman Kyrychynskyi.

Committee leadership is distributed as follows: • Audit Committee: chaired by Roman Kyrychynskyi, with Chuen Yan Leung, Ph.D.; Denitsa Milanova, Ph.D.; and Jingsong Wang, Ph.D. as members. • Remuneration Committee: chaired by Jingsong Wang, Ph.D., with Denitsa Milanova, Ph.D.; Roman Kyrychynskyi; and Feng Ren, Ph.D. serving as members. • Nomination Committee: chaired by Aleksandrs Zavoronkovs, Ph.D., joined by Denitsa Milanova, Ph.D.; Jingsong Wang, Ph.D.; and Roman Kyrychynskyi. • ESG Committee: chaired by Feng Ren, Ph.D., with Aleksandrs Zavoronkovs, Ph.D.; Denitsa Milanova, Ph.D.; Jingsong Wang, Ph.D.; and Roman Kyrychynskyi as members.

The announcement clarifies committee responsibilities and reinforces the company’s governance structure by designating independent directors to chair both the Audit and Remuneration Committees.